Background: The aim of this study was to examine the course of poststroke fatigue in a cohort of first-time stroke patients compared to the general population, and to identify clinically relevant features of post-stroke fatigue. Methods: We performed a follow-up study of 165 patients with first-time stroke admitted to acute stroke units at the Aarhus University Hospital, Denmark. A reference group of 1,069 persons was sampled from the general population. Fatigue was assessed using the Multidimensional Fatigue Inventory (MFI-20) covering five scales of fatigue (General Fatigue, Physical Fatigue, Reduced Activity, Reduced Motivation, and Mental Fatigue). Results: Compared to the general population, stroke patients reported higher levels of Physical Fatigue. Minor or no differences were found for the other fatigue scales. Pathological fatigue, defined as a score ≧12 on the General Fatigue scale, was reported by 59% (95% CI: 51–66%), 44% (95% CI: 36–51%), 38% (95% CI: 31–46%), and 40% (95% CI: 32–48%) of stroke patients 10 days, 3 months, 1 year, and 2 years following hospitalization for stroke, respectively. Post-stroke fatigue levels decreased after three months and remained stable throughout the remainder of follow-up. Poor functional outcome was consistently associated with increased levels of fatigue. Conclusions: Post-stroke fatigue is a common condition primarily characterized by increased levels of Physical Fatigue. The pathological mechanisms underlying post-stroke fatigue and its clinical implications require further study.

Keywords:
Fatigue, Cerebrovascular accident, Follow-up studies
1.
Choi-Kwon S, Han SW, Kwon SU, Kim JS: Poststroke fatigue: Characteristics and related factors. Cerebrovasc Dis 2005;19:84–90.
2.
Colle F, Bonan I, Gellez Leman MC, Bradai N, Yelnik A: Fatigue after stroke. Ann Readapt Med Phys 2006;49:272–276.
3.
Glader EL, Stegmayr B, Asplund K: Poststroke fatigue: a 2-year follow-up study of stroke patients in Sweden. Stroke 2002;33:1327–1333.
4.
Ingles JL, Eskes GA, Phillips SJ: Fatigue after stroke. Arch Phys Med Rehabil 1999;80:173–178.
5.
Naess H, Nyland HI, Thomassen L, Aarseth J, Myhr KM: Fatigue at long-term follow-up in young adults with cerebral infarction. Cerebrovasc Dis 2005;20:245–250.
6.
Schepers VP, Visser-Meily AM, Ketelaar M, Lindeman E: Poststroke fatigue: course and its relation to personal and stroke-related factors. Arch Phys Med Rehabil 2006;87:184–188.
7.
Staub F, Bogousslavsky J: Fatigue after stroke: a major but neglected issue. Cerebrovasc Dis 2001;12:75–81.
8.
van der Werf SP, van den Broek HL, Anten HW, Bleijenberg G: Experience of severe fatigue long after stroke and its relation to depressive symptoms and disease characteristics. Eur Neurol 2001;45:28–33.
9.
van de Port IG, Kwakkel G, Schepers VP, Heinemans CT, Lindeman E: Is fatigue an independent factor associated with activities of daily living, instrumental activities of daily living and health-related quality of life in chronic stroke? Cerebrovasc Dis 2006;23:40–45.
10.
Appelros P: Prevalence and predictors of pain and fatigue after stroke: a population-based study. Int J Rehabil Res 2006;29:329–333.
11.
De Groot MH, Phillips SJ, Eskes GA: Fatigue associated with stroke and other neurologic conditions: Implications for stroke rehabilitation. Arch Phys Med Rehabil 2003;84:1714–1720.
12.
Bendz M: The first year of rehabilitation after a stroke: from two perspectives. Scand J Caring Sci 2003;17:215–222.
13.
Burton CR: Living with stroke: a phenomenological study. J Adv Nurs 2000;32:301–309.
14.
Carlsson GE, Moller A, Blomstrand C: A qualitative study of the consequences of ‘hidden dysfunctions’ one year after a mild stroke in persons <75 years. Disabil Rehabil 2004;26:1373–1380.
15.
Kirkevold M: The unfolding illness trajectory of stroke. Disabil Rehabil 2002;24:887–898.
16.
Patel MD, Tilling K, Lawrence E, Rudd AG, Wolfe CD, McKevitt C: Relationships between long-term stroke disability, handicap and health-related quality of life. Age Ageing 2006;35:273–279.
17.
Secrest JA, Thomas SP: Continuity and discontinuity: the quality of life following stroke. Rehabil Nurs 1999;24:240–246.
18.
Suenkeler IH, Nowak M, Misselwitz B, Kugler C, Schreiber W, Oertel WH, Back T: Timecourse of health-related quality of life as determined 3, 6 and 12 months after stroke: relationship to neurological deficit, disability and depression. J Neurol 2002;249:1160–1167.
19.
Naess H, Waje-Andreassen U, Thomassen L, Nyland H, Myhr KM: Health-related quality of life among young adults with ischemic stroke on long-term follow-up. Stroke 2006;37:1232–1236.
20.
Carlsson GE, Moller A, Blomstrand C: Consequences of mild stroke in persons <75 years: a 1-year follow-up. Cerebrovasc Dis 2003;16:383–388.
21.
Michael KM, Allen JK, Macko RF: Fatigue after stroke: relationship to mobility, fitness, ambulatory activity, social support, and falls efficacy. Rehabil Nurs 2006;31:210–217.
22.
Morley W, Jackson K, Mead GE: Post-stroke fatigue: an important yet neglected symptom. Age Ageing 2005;34:313.
23.
Dittner AJ, Wessely SC, Brown RG: The assessment of fatigue: a practical guide for clinicians and researchers. J Psychosom Res 2004;56:157–170.
24.
Smets EM, Garssen B, Bonke B, Dehaes JCJM: The Multidimensional Fatigue Inventory (MFI) Psychometric Qualities of an Instrument to assess fatigue. J Psychosom Res 1995;39:315–325.
25.
Aho K, Harmsen P, Hatano S, Marquardsen J, Smirnov VE, Strasser T: Cerebrovascular disease in the community: results of a WHO collaborative study. Bull World Health Org 1980;58:113–130.
26.
Mainz J, Krog BR, Bjørnshave B, Bartels P: Nationwide continuous quality improvement using clinical indicators: the Danish National Indicator Project. Int J Qual Health Care 2004;16:i45–i50.
27.
Referenceprogram for behandling af patienter med apopleksi. Copenhagen, Danish Board of Health, available at: www.sst.dk/publ/Publ2006/CEMTV/SfR/Apopl_refprg.pdf [in Danish].
28.
Andersen G, Vestergaard K, Lauritzen L: Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994;25:1099–1104.
29.
Watt T, Groenvold M, Bjorner JB, Noerholm V, Rasmussen NA, Bech P: Fatigue in the Danish general population: influence of sociodemographic factors and disease. J Epidemiol Community Health 2000;54:827–833.
30.
Holzner B, Kemmler G, Meraner V, Maislinger A, Kopp M, Bodner T, Nguyen-Van-Tam D, Zeimet AG, Fleischhacker WW, Sperner-Unterweger B: Fatigue in ovarian carcinoma patients: a neglected issue? Cancer 2003;97:1564–1572.
31.
Jorgensen HS, Nakayama H, Raaschou HO, Vive-Larsen J, Stoier M, Olsen TS: Outcome and time course of recovery in stroke. II. Time course of recovery. The Copenhagen Stroke Study. Arch Phys Med Rehabil 1995;76:406–412.
32.
Mahoney FI, Barthel DW: Functional evaluation: the Barthel Index. Md State Med J 1965;14:61–65.
33.
Sulter G, Steen C, De Keyser J: Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 1999;30:1538–1541.
34.
Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521–1526.
35.
Bech P, Wermuth L: Applicability and validity of the Major Depression Inventory in patients with Parkinson’s disease. Nord J Psychiatry 1998;52:305–309.
36.
Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373–383.
37.
Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–619.
38.
Goldstein LB, Samsa GP, Matchar DB, Horner RD: Charlson Index comorbidity adjustment for ischemic stroke outcome studies. Stroke 2004;35:1941–1945.
39.
Meek PM, Nail LM, Barsevick A, Schwartz AL, Stephen S, Whitmer K, Beck SL, Jones LS, Walker BL: Psychometric testing of fatigue instruments for use with cancer patients. Nurs Res 2000:49:181–190.
40.
Choi-Kwon S, Choi J, Kwon SU, Kang DW, Kim JS: Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study. Cerebrovasc Dis 2007:23:103–108.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.